Table 2 Subgroup analysis in countries with high prevalence of HCV infection
Outcome | Studies | HR/OR (95%CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|
I2% | P value | ||||
Impact of HCV infection | |||||
Overall survival | 7 | 2.07 (1.37–3.14) | 0.0006 | 61 | 0.02 |
Progression-free survival | 2 | 1.89 (1.27–2.82) | 0.002 | 0 | 0.66 |
Overall response rate | 6 | 0.51 (0.38–0.68) | < 0.00001 | 46 | 0.10 |
Hepatic dysfunction | 2 | 30.13 (1.75–517.77) | 0.02 | 84 | 0.01 |
Age of onset | 5 | 1.04 (0.50–2.16) | 0.92 | 79 | 0.0009 |
Advanced disease stage | 11 | 1.53 (1.22–1.91) | 0.0002 | 44 | 0.06 |
Presence of B symptom | 6 | 0.99 (0.53–1.84) | 0.97 | 63 | 0.02 |
Elevated LDH level | 5 | 1.33 (0.96–1.84) | 0.09 | 49 | 0.10 |
H-I/H risk | 6 | 1.53 (0.96–2.44) | 0.07 | 60 | 0.03 |
Spleen involvement | 4 | 3.74 (2.32–6.02) | < 0.00001 | 0 | 0.52 |
Liver involvement | 5 | 1.98 (1.23–3.20) | 0.005 | 41 | 0.15 |
Bone marrow involvement | 6 | 1.39 (0.97–2.00) | 0.07 | 46 | 0.10 |